-
2022-502779-40-00
5
2023-09-04
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-515027-11-00
4
2023-06-29
Crohn’s disease
-
2022-501506-36-00
5
2023-04-11
First-line treatment of participants with metastatic nonsmall cell lun
-
2022-500014-26-00
5
2022-06-24
Locally-Advanced unresectable or Metastatic breast cancer (MBC)
-
2023-509631-37-00
5
2022-01-18
"Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-516039-28-00
6
2021-09-28
Spontaneous Coronary Artery Dissection.
-
2023-508308-40-00
5
2021-07-30
Metastatic (stage IV) squamous or nonsquamous non-small cell lung canc
-
2024-510750-28-00
4
2021-06-18
Tumours of the urothelial tract requiring surgery (T1 high grade-T4a o
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-505810-12-00
5
2019-09-03
Lower limb spasticity
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-504951-29-00
5
2017-07-27
Chron's Disease
-
2023-507376-50-00
1
2024-09-27
Ulcerative Colitis
-
2023-508440-21-00
5
2024-05-21
Infections due to Enterobacteriaceae
-
2023-504678-39-00
4
2024-03-13
Heart Failure
-
2023-503576-25-00
5
2023-09-22
Severe Hypertriglyceridemia
-
2022-500449-26-00
6
2023-08-03
Type 2 diabetes mellitus (T2DM)
-
2022-500536-11-01
5
2023-06-08
Moderately to severely active ulcerative colitis
-
2024-514293-46-00
4
2022-07-07
Unresectable locally advanced or metastatic urothelial cancer
-
2024-518403-22-00
6
2022-06-20
Diabetes mellitus II
-
2024-519633-35-00
6
2021-10-25
Resectable pancreatic adenocarcinoma with risk factors